drugset / Trial / NCT02461771
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
Non-randomizedSequentialOpen-labelTreatment
Summary
The objective of this study is to provide initial safety, tolerability and pharmacokinetics information of intravitreal administration of pegcetacoplan in order to support further development into larger Phase II studies for treatment of patients with AMD.
Timeline
- Start
- 2015-01-28
- Primary completion
- 2016-03-08
- Completion
- 2016-03-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegcetacoplan | Peptide | 4 mg | Intravitreal |
| Subject | Pegcetacoplan | Peptide | 10 mg | Intravitreal |
| Subject | Pegcetacoplan | Peptide | 20 mg | Intravitreal |